{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:36:50Z","timestamp":1782193010443,"version":"3.54.5"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ceva Sante Animale"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To characterize the dose-exposure-response effect of spironolactone on biomarkers of the classical and alternative arms of the renin-angiotensin-aldosterone system (RAAS) in healthy dogs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Animals<\/jats:title>\n<jats:p>Ten healthy purpose-bred Beagle dogs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Procedures<\/jats:title>\n<jats:p>Study dogs were randomly allocated to 2 spironolactone dosing groups (2 mg\/kg PO q24hr, 4 mg\/kg PO q24hr). The dogs received 7-day courses of spironolactone followed by a 14-day washout period in a crossover (AB\/BA) design. Angiotensin peptides and aldosterone were measured in serum using equilibrium analysis, and plasma canrenone and 7-\u03b1-thiomethyl spironolactone (TMS) were quantified via liquid chromatography-mass spectrometry\/mass spectroscopy (LC-MS\/MS). Study results were compared before and after dosing and between groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>Following spironolactone treatment, dogs had a significant increase in serum aldosterone concentration (<jats:italic>P<\/jats:italic> = 0.07), with no statistical differences between dosing groups. Significant increases in angiotensin II (<jats:italic>P<\/jats:italic> = 0.09), angiotensin I (<jats:italic>P<\/jats:italic> = 0.08), angiotensin 1\u20135 (<jats:italic>P<\/jats:italic> = 0.08), and a surrogate marker for plasma renin activity (<jats:italic>P<\/jats:italic> = 0.06) were detected compared to baseline following spironolactone treatment during the second treatment period only. Overall, changes from baseline did not significantly differ between spironolactone dosages. RAAS analytes were weakly correlated (R &lt; 0.4) with spironolactone dosage and plasma canrenone or plasma TMS. There were no adverse clinical or biochemical effects seen at any spironolactone dosage during treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Treatment with spironolactone increased serum aldosterone concentration in healthy dogs and impacted other biomarkers of the classical and alternative arms of the RAAS. There was no difference in effect on the RAAS between 2 and 4 mg\/kg\/day dosing. Dosage of 4 mg\/kg\/day was safe and well-tolerated in healthy dogs.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0298030","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T18:58:10Z","timestamp":1708714690000},"page":"e0298030","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comprehensive characterization of the effect of mineralocorticoid receptor antagonism with spironolactone on the renin-angiotensin-aldosterone system in healthy dogs"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-7699","authenticated-orcid":true,"given":"Allison K.","family":"Masters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Domenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingnan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0997-3111","authenticated-orcid":true,"given":"Jonathan P.","family":"Mochel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"pone.0298030.ref001","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"B Pitt","year":"2008","journal-title":"New Engl J Med"},{"key":"pone.0298030.ref002","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1939-1676.2009.0467.x","article-title":"Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease","volume":"24","author":"F Bernay","year":"2010","journal-title":"J Vet Intern Med"},{"key":"pone.0298030.ref003","first-page":"1","article-title":"Clinical efficacy of benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The Benazepril Spironolactone Study (BESST)","author":"M Coffman","year":"2021","journal-title":"J Vet Intern Med"},{"key":"pone.0298030.ref004","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"AS Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"pone.0298030.ref005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/hrt.82.1.57","article-title":"How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?","volume":"82","author":"RJ MacFadyen","year":"1999","journal-title":"Heart"},{"key":"pone.0298030.ref006","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","article-title":"Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy","volume":"16","author":"A Sato","year":"2003","journal-title":"Am J Hypertens"},{"key":"pone.0298030.ref007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jvp.12154","article-title":"Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs","volume":"38","author":"AC Lantis","year":"2015","journal-title":"J Vet Pharmacol Ther"},{"key":"pone.0298030.ref008","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jvp.12216","article-title":"The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs","volume":"38","author":"AC Lantis","year":"2015","journal-title":"J Vet Pharmacol Ther"},{"key":"pone.0298030.ref009","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2460\/ajvr.76.12.1041","article-title":"Effect of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs","volume":"76","author":"MK Ames","year":"2015","journal-title":"Am J Vet Res"},{"key":"pone.0298030.ref010","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jvc.2017.03.001","article-title":"Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease","volume":"19","author":"MK Ames","year":"2017","journal-title":"J Vet Cardiol"},{"key":"pone.0298030.ref011","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1111\/jvim.16573","article-title":"Prevalence of aldosterone breakthrough in dogs receiving renin-angiotensin system inhibitors for proteinuric chronic kidney disease","volume":"36","author":"MK Ames","year":"2022","journal-title":"J Vet Intern Med"},{"key":"pone.0298030.ref012","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/jvim.15488","article-title":"ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs","volume":"33","author":"BW Keene","year":"2019","journal-title":"J Vet Intern Med"},{"key":"pone.0298030.ref013","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jvc.2017.06.001","article-title":"Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone\u2014a pilot study","volume":"19","author":"MJ Hezzell","year":"2017","journal-title":"J Vet Cardiol"},{"key":"pone.0298030.ref014","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jvc.2021.06.001","article-title":"Prospective clinical trial evaluating spironolactone in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy","volume":"40","author":"A Laskary","year":"2022","journal-title":"J Vet Cardiol"},{"key":"pone.0298030.ref015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/jvim.16687","article-title":"The classical and alternative circulating renin-angiotensin system in normal dogs and dogs with stage B1 and B2 myxomatous mitral valve disease","volume":"37","author":"HK Hammond","year":"2023","journal-title":"J Vet Intern Med"},{"key":"pone.0298030.ref016","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2885.2010.01235.x","article-title":"Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs","volume":"34","author":"S Schuler","year":"2011","journal-title":"J Vet Pharmacol Ther"},{"key":"pone.0298030.ref017","unstructured":"PRILACTONE\u00ae 10mg, 40mg, & 80mg (Spironolactone) [package insert]. Libourne, France: Ceva Sant\u00e9 Animale; 2004."},{"key":"pone.0298030.ref018","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/j.ctsap.2005.05.005","article-title":"How to obtain a blood pressure measurement","volume":"20","author":"RA Henic","year":"2005","journal-title":"Clin Tech Small Anim Pract"},{"key":"pone.0298030.ref019","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"P Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"key":"pone.0298030.ref020","doi-asserted-by":"crossref","first-page":"B27","DOI":"10.1093\/eurheartj\/sur009","article-title":"Physiology of aldosterone and pharmacology of aldosterone blockers","volume":"13","author":"AD Struthers","year":"2011","journal-title":"Eur Heart J Supplements"},{"key":"pone.0298030.ref021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep33678","article-title":"Neprilysin is a mediator of alternative renin-angiotensin-system activation in the murine and human kidney","volume":"6","author":"O Domenig","year":"2016","journal-title":"Sci Rep"},{"key":"pone.0298030.ref022","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/jvim.15948","article-title":"Effect of angiotensin receptor blockers and angiotensin-converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease","volume":"35","author":"T Huh","year":"2021","journal-title":"J Vet Intern Med"},{"key":"pone.0298030.ref023","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/clinchem\/hvaa001","article-title":"Measurement of equilibrium angiotensin II in the diagnosis of primary aldosteronism","volume":"66","author":"Z Guo","year":"2020","journal-title":"Clin Chem"},{"key":"pone.0298030.ref024","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/jvim.15746","article-title":"Renin-angiotensin aldosterone profile before and after angiotensin-converting enzyme-inhibitor administration in dogs with angiotensin-converting enzyme gene polymorphism","volume":"34","author":"D Adin","year":"2020","journal-title":"J Vet Intern Med"},{"key":"pone.0298030.ref025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jvc.2007.10.002","article-title":"Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs","volume":"9","author":"E Jeunesse","year":"2007","journal-title":"J Vet Cardiol"},{"key":"pone.0298030.ref026","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2885.2009.01130.x","article-title":"A preclinical pharmacokinetic and pharmacodynamics approach to determine a dose of spironolactone for treatment of congestive heart failure in dogs","volume":"33","author":"J Guyonnet","year":"2010","journal-title":"J Vet Pharmacol Ther"},{"key":"pone.0298030.ref027","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/jvim.12141","article-title":"Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study","volume":"27","author":"HP Lefebvre","year":"2013","journal-title":"J Vet Intern Med"},{"key":"pone.0298030.ref028","first-page":"F381","article-title":"Renal and systemic acid-base effects of chronic spironolactone administration","volume":"240","author":"HN Hulter","year":"1981","journal-title":"Am J Physiol"},{"key":"pone.0298030.ref029","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jvc.2019.12.002","article-title":"DELay of Appearance of sYmptoms of canine degenerative mitral valve disease treated with spironolactone and benazepril: the DELAY study","volume":"27","author":"M Borgarelli","year":"2020","journal-title":"J Vet Cardiol"},{"key":"pone.0298030.ref030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/jvim.15662","article-title":"Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease","volume":"34","author":"D Adin","year":"2020","journal-title":"J Vet Intern Med"},{"key":"pone.0298030.ref031","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1042\/cs0620465","article-title":"The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog","volume":"62","author":"AJG Riegger","year":"1982","journal-title":"Clin Sci"},{"key":"pone.0298030.ref032","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1172\/JCI108431","article-title":"The renin angiotensin aldosterone system in congestive failure in conscious dogs","volume":"57","author":"L Watkins","year":"1976","journal-title":"J Clin Invest"},{"key":"pone.0298030.ref033","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS)","volume":"118","author":"B Pitt","year":"2008","journal-title":"Circulation"},{"key":"pone.0298030.ref034","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jvc.2007.08.002","article-title":"Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg2+, and Na+ concentrations in small dogs with degenerative mitral valve disease","volume":"9","author":"JD Thomason","year":"2007","journal-title":"J Vet Cardiol"},{"key":"pone.0298030.ref035","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3109\/07420528.2013.807275","article-title":"Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology","volume":"30","author":"JP Mochel","year":"2013","journal-title":"Chronobiol Int"},{"key":"pone.0298030.ref036","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3109\/07420528.2014.897711","article-title":"Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs","volume":"31","author":"JP Mochel","year":"2014","journal-title":"Chronobiol Int"},{"key":"pone.0298030.ref037","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nmeth.3288","article-title":"The fickle P value generates irreproducible results","volume":"12","author":"LG Halsey","year":"2015","journal-title":"Nat Methods"},{"key":"pone.0298030.ref038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1098\/rsbl.2019.0174","article-title":"The reign of the p-value is over: What alternative analyses could we employ to fill the power vacuum?","volume":"15","author":"LG Halsey","year":"2019","journal-title":"Biol Lett"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0298030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T18:58:45Z","timestamp":1708714725000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0298030"}},"subtitle":[],"editor":[{"given":"Doa\u2019a G. F.","family":"Al-u\u2019datt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0298030","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]}}}